Evaluation of the clinical-diffusion and perfusion-diffusion mismatch models in DEFUSE

Stroke

Volumn 38, Issue 6, 2007, Pages 1826-1830

  Lansberg, Maarten G ^a,d   Thijs, Vincent N ^b   Hamilton, Scott ^a   Schlaug, Gottfried ^c   Bammer, Roland ^a   Kemp, Stephanie ^a   Albers, Gregory W ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c HARVARD MEDICAL SCHOOL   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

Acute treatment; Diffusion weighted MRI; Ischemic stroke; Outcome; Perfusion weighted MRI; Plasminogen activator; Reperfusion

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

AGED; ARTICLE; BRAIN PERFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIFFUSION; FEMALE; HUMAN; MALE; MODEL; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PATIENT SELECTION; PRIORITY JOURNAL; REPERFUSION; STROKE; SYMPTOM; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; CEREBROVASCULAR ACCIDENT; DIFFUSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, CARDIOVASCULAR; MULTICENTER STUDIES; PERFUSION; PROSPECTIVE STUDIES; REPERFUSION; RETROSPECTIVE STUDIES; THROMBOLYTIC THERAPY;

EID: 34249799294     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.106.480145     Document Type: Article

References (20)

1. Tissue plasminogen activator for acute ischemic stroke. The national institute of neurological disorders and stroke rt-PA stroke study group. N Engl J Med. 1995;333:1581-1587.
2. Association of outcome with early stroke treatment: Pooled analysis of Atlantis, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363: 768-774.
3. Albers GW. Expanding the window for thrombolytic therapy in acute stroke. The potential role of acute MRI for patient selection. Stroke. 1999;30:2230-2237.
4. Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, Skalabrin E, Bammer R, Kakuda W, Lansberg MG, Shuaib A, Coplin W, Hamilton S, Moseley M, Marks MP, for the DEFUSE Investigators. Magnetic resonance imaging profiles predict clinical response to early reperfusion: The diffusion and perfusion imaging evaluation for understanding stroke evolution (defuse) study. Ann Neurol. 2006;60:508-517.
5. Davalos A, Blanco M, Pedraza S, Leira R, Castellanos M, Pumar JM, Silva Y, Serena J, Castillo J. The clinical-DWI mismatch: A new diagnostic approach to the brain tissue at risk of infarction. Neurology. 2004;62:2187-2192.
6. Ostergaard L, Weisskoff RM, Chesler DA, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis. Magn Reson Med. 1996;36:715-725.
7. Ostergaard L, Sorensen AG, Kwong KK, Weisskoff RM, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part ii: Experimental comparison and preliminary results. Magn Reson Med. 1996;36:726-736.
8. Thijs VN, Somford DM, Bammer R, Robberecht W, Moseley ME, Albers GW. Influence of arterial input function on hypoperfusion volumes measured with perfusion-weighted imaging. Stroke. 2004;35:94-98.
9. Altman DG, Bland JM. Interaction revisited: The difference between two estimates. BMJ. 2003;326:219.
10. Schellinger PD, Fiebach JB, Hacke W. Imaging-based decision making in thrombolytic therapy for ischemic stroke: Present status. Stroke. 2003; 34:575-583.
11. Davis SM, Donnan GA, Butcher KS, Parsons M. Selection of thrombolytic therapy beyond 3 h using magnetic resonance imaging. Curr Opin Neurol. 2005;18:47-52.
12. Warach S. New imaging strategies for patient selection for thrombolytic and neuroprotective therapies. Neurology. 2001;57:S48-S52.
13. Kohrmann M, Juttler E, Fiebach JB, Huttner HB, Siebert S, Schwark C, Ringleb PA, Schellinger PD, Hacke W. MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study. The Lancet Neurology. 2006;5:661-667.
14. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S, for The DIAS Study Group. The desmoteplase in acute ischemic stroke trial (dias): A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36:66-73.
15. Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, Sachara C, Soehngen M, Warach S, Hacke W, for the DEDAS Investigators. Dose escalation of desmoteplase for acute ischemic stroke (DEDAS): Evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. 2006;37:1227-1231.
16. Prosser J, Butcher K, Allport L, Parsons M, MacGregor L, Desmond P, Tress B, Davis S. Clinical-diffusion mismatch predicts the putative penumbra with high specificity. Stroke. 2005;36:1700-1704.
17. Nighoghossian N, Hermier M, Adeleine P, Derex L, Dugor JF, Philippeau F, Ylmaz H, Honnorat J, Dardel P, Berthezene Y, Froment JC, Trouillas P. Baseline magnetic resonance imaging parameters and stroke outcome in patients treated by intravenous tissue plasminogen activator. Stroke. 2003;34:458-463.
18. Rivers CS, Wardlaw JM, Armitage PA, Bastin ME, Carpenter TK, Cvoro V, Hand PJ, Dennis MS. Do acute diffusion- and perfusion-weighted mri lesions identify final infarct volume in ischemic stroke? Stroke. 2006;37: 98-104.
19. Tong DC, Yenari MA, Albers GW, O'Brien M, Marks MP, Moseley ME. Correlation of perfusion- and diffusion-weighted mri with nihss score in acute (<6.5 hour) ischemic stroke. Neurology. 1998;50:864-870.
20. Shih LC, Saver JL, Alger JR, Starkman S, Leary MC, Vinuela F, Duckwiler G, Gobin YP, Jahan R, Villablanca JP, Vespa PM, Kidwell CS. Perfusion-weighted magnetic resonance imaging thresholds identifying core, irreversibly infarcted tissue. Stroke. 2003;34:1425-1430.